LKQ Corporation Announces Results For Third Quarter 2026

LKQ’s Q3 2026 revenue fell 5.1% to $3.319 billion, while adjusted diluted EPS declined to $0.50 from $0.84 a year earlier; reported results included a $24 million net loss and $111 million in pre-tax non-cash impairment charges. Europe revenue dropped 10.2%, with management citing Germany ERP implementation issues and volume declines in the UK and Benelux; the company withdrew its 2026 guidance. The board suspended its strategic review, including the Specialty sale process, as it prepares for incoming CEO Sal Abbate, effective December 15, 2026.

Analysis

The key issue is not the impairment itself, but whether Europe’s execution failure has exposed a lower sustainable earnings base. Europe’s EBITDA contraction substantially exceeded its revenue decline, consistent with negative operating leverage; a successful Germany ERP stabilization could reverse some of that quickly, but UK/Benelux volume weakness makes a purely one-off explanation incomplete. North America’s comparatively steadier performance is not yet enough to offset the European drag, while Specialty’s modest revenue growth alongside lower segment EBITDA weakens the near-term case for a clean carve-out premium.

The suspended Specialty sale removes a near-term valuation catalyst and leaves the new CEO with competing priorities: repair Europe, assess the portfolio, and address a reset in earnings expectations. A&M involvement and leadership changes are process signals, not proof of recoverable margins. Adjusted results also exclude recurring restructuring and acquisition-related amortization; investors should anchor on segment EBITDA and cash conversion, not assume every adjustment is temporary. Buybacks may cushion supply, but at 2.8x leverage and with a broad operational review underway, capital returns compete with debt capacity and turnaround investment.

Near term, expect elevated volatility around the conference call and any clarification of Europe’s recovery timeline. Over 1–3 months, Germany service levels, organic volumes, and segment profitability matter more than headline revenue. Over 6–18 months, successful execution could restore earnings power; failure would risk further impairments and a lower multiple. Contrarian upside exists if the ERP issue is contained and the CEO rapidly improves execution, but the guidance withdrawal and paused sale make the burden of proof lie with management.

Key Decisions for Investors

• Underweight LKQ; consider initiating a modest tactical short on any post-results relief rally rather than chasing the initial reaction. No valuation-based target is supportable without current price and consensus data. Reassess if Europe segment EBITDA stabilizes and organic sales trends improve.
• Use the next 1–3 quarters as a verification window: track Germany order fill/service levels, Europe organic revenue, and Europe EBITDA margin. A continued decline in Europe profitability despite ERP remediation would falsify the turnaround thesis and strengthen the short; sequential stabilization would warrant covering.
• Do not treat the extended buyback authorization as a firm demand floor. Monitor actual repurchases, leverage, and free cash flow conversion; prioritize operating evidence over capital-return announcements.
• Watch for renewed Specialty-sale activity only after leadership review. A credible transaction process could restore optionality, but an extended pause or additional asset impairments would keep the strategic-discount risk elevated.